StreetInsider.com News Articles

Hua Medicine Announces the Approval of Dorzagliatin for Marketing in Hong Kong SAR, China

Mon, 02 Mar 2026 22:14:00 -0400

Shanghai, Hong Kong, Mar 3, 2026 - (JCN Newswire) - - - First glucokinase-activator (GKA) approval outside mainland China

- Approval supports a differentiated approach to Type 2 diabetes (T2D) management

- Hong Kong will serve as Hua Medicine's launchpad for international market expansion

Hua Medicine ("the Company", Hong Kong Stock Exchange Stock Code: 2552.HK) announced today that its global first-in-class glucokinase activator (GKA) dorzagliatin (Trade name: MYHOMSIS(R)) has been approved for marketing by the Pharmaceutical Service of the Department of Health of the Hong Kong Special Administrative Region of China for the treatment of Type 2 diabetes in adults.

Under Hong Kong's

Hua Medicine Announces the Approval of Dorzagliatin for Marketing in Hong Kong SAR, China

Mon, 02 Mar 2026 22:14:00 -0400

Shanghai, Hong Kong, Mar 3, 2026 - (JCN Newswire) - - - First glucokinase-activator (GKA) approval outside mainland China

- Approval supports a differentiated approach to Type 2 diabetes (T2D) management

- Hong Kong will serve as Hua Medicine's launchpad for international market expansion

Under Hong Kong's

Hua Medicine Announces the Approval of Dorzagliatin for Marketing in Hong Kong SAR, China

Mon, 02 Mar 2026 22:14:00 -0400

Shanghai, Hong Kong, Mar 3, 2026 - (JCN Newswire) - - - First glucokinase-activator (GKA) approval outside mainland China

- Approval supports a differentiated approach to Type 2 diabetes (T2D) management

- Hong Kong will serve as Hua Medicine's launchpad for international market expansion

Under Hong Kong's

Hua Medicine Announces the Approval of Dorzagliatin for Marketing in Hong Kong SAR, China

Mon, 02 Mar 2026 22:14:00 -0400

Shanghai, Hong Kong, Mar 3, 2026 - (JCN Newswire) - - - First glucokinase-activator (GKA) approval outside mainland China

- Approval supports a differentiated approach to Type 2 diabetes (T2D) management

- Hong Kong will serve as Hua Medicine's launchpad for international market expansion

Under Hong Kong's

Hua Medicine Announces the Approval of Dorzagliatin for Marketing in Hong Kong SAR, China

Mon, 02 Mar 2026 22:14:00 -0400

Shanghai, Hong Kong, Mar 3, 2026 - (JCN Newswire) - - - First glucokinase-activator (GKA) approval outside mainland China

- Approval supports a differentiated approach to Type 2 diabetes (T2D) management

- Hong Kong will serve as Hua Medicine's launchpad for international market expansion

Under Hong Kong's

Hua Medicine Announces the Approval of Dorzagliatin for Marketing in Hong Kong SAR, China

Mon, 02 Mar 2026 22:14:00 -0400

Shanghai, Hong Kong, Mar 3, 2026 - (JCN Newswire) - - - First glucokinase-activator (GKA) approval outside mainland China

- Approval supports a differentiated approach to Type 2 diabetes (T2D) management

- Hong Kong will serve as Hua Medicine's launchpad for international market expansion

Under Hong Kong's

Hua Medicine Announces the Approval of Dorzagliatin for Marketing in Hong Kong SAR, China

Mon, 02 Mar 2026 22:14:00 -0400

Shanghai, Hong Kong, Mar 3, 2026 - (JCN Newswire) - - - First glucokinase-activator (GKA) approval outside mainland China

- Approval supports a differentiated approach to Type 2 diabetes (T2D) management

- Hong Kong will serve as Hua Medicine's launchpad for international market expansion

Under Hong Kong's

Hua Medicine Announces the Approval of Dorzagliatin for Marketing in Hong Kong SAR, China

Mon, 02 Mar 2026 22:14:00 -0400

Shanghai, Hong Kong, Mar 3, 2026 - (JCN Newswire) - - - First glucokinase-activator (GKA) approval outside mainland China

- Approval supports a differentiated approach to Type 2 diabetes (T2D) management

- Hong Kong will serve as Hua Medicine's launchpad for international market expansion

Under Hong Kong's

Hua Medicine Announces the Approval of Dorzagliatin for Marketing in Hong Kong SAR, China

Mon, 02 Mar 2026 22:14:00 -0400

Shanghai, Hong Kong, Mar 3, 2026 - (JCN Newswire) - - - First glucokinase-activator (GKA) approval outside mainland China

- Approval supports a differentiated approach to Type 2 diabetes (T2D) management

- Hong Kong will serve as Hua Medicine's launchpad for international market expansion

Under Hong Kong's

Hua Medicine Announces the Approval of Dorzagliatin for Marketing in Hong Kong SAR, China

Mon, 02 Mar 2026 22:14:00 -0400

Shanghai, Hong Kong, Mar 3, 2026 - (JCN Newswire) - - - First glucokinase-activator (GKA) approval outside mainland China

- Approval supports a differentiated approach to Type 2 diabetes (T2D) management

- Hong Kong will serve as Hua Medicine's launchpad for international market expansion

Under Hong Kong's

Hua Medicine Announces 2025 Interim Results

Thu, 28 Aug 2025 04:07:00 -0400

SHANGHAI, Aug 28, 2025 - (ACN Newswire) - - - Sales of HuaTangNing increased by 108% year-on-year, with net sales increasing by 112% year-on-year. Reimbursement coverage continued to expand, with a significant increase in prescription volumes across Tier 2 and Tier 3 hospitals, as our comprehensive commercialization strategy achieved significant results.

- Following the termination of the exclusive promotion service agreement with Bayer, the Company recognized a one-time release of previously deferred income of RMB 1,243.5 million, achieving a profit of RMB 1,183.9 million for the first half of the year. This is the Company's first profit during the performance

Hua Medicine Announces 2025 Interim Results

Thu, 28 Aug 2025 04:07:00 -0400

Hua Medicine Announces 2025 Interim Results

Thu, 28 Aug 2025 04:07:00 -0400

Hua Medicine Announces 2025 Interim Results

Thu, 28 Aug 2025 04:07:00 -0400

Hua Medicine Announces 2025 Interim Results

Thu, 28 Aug 2025 04:07:00 -0400

Hua Medicine Announces 2025 Interim Results

Thu, 28 Aug 2025 04:07:00 -0400

Hua Medicine Announces 2025 Interim Results

Thu, 28 Aug 2025 04:07:00 -0400

Hua Medicine Announces 2025 Interim Results

Thu, 28 Aug 2025 04:07:00 -0400

Hua Medicine Announces at 2025 ADA Scientific Sessions that Dorzagliatin Combined with DPP-4 Inhibitor Shows Promise in Reducing Blood Lipids While Restoring Glucose Homeostasis

Sun, 22 Jun 2025 23:05:00 -0400

HONG KONG, Jun 23, 2025 - (JCN Newswire) - - Hua Medicine ("the Company", stock code: 2552.HK) announced today that the Company presented the latest research results of dorzagliatin, its global first-in-class glucokinase activator (GKA), at the 85th Scientific Sessions of the American Diabetes Association (ADA). A preclinical animal study showed that the combination of dorzagliatin and sitagliptin, a DPP-4 inhibitor, improves blood glucose levels, promotes insulin secretion, and enhances GLP-1 secretion. The combination therapy was more effective than dorzagliatin alone. The blood chemistry analysis further indicates that the combination therapy has potential benefits for lipid lowering (especially LDL)

Hua Medicine Announces at 2025 ADA Scientific Sessions that Dorzagliatin Combined with DPP-4 Inhibitor Shows Promise in Reducing Blood Lipids While Restoring Glucose Homeostasis

Sun, 22 Jun 2025 23:05:00 -0400

Hua Medicine Announces at 2025 ADA Scientific Sessions that Dorzagliatin Combined with DPP-4 Inhibitor Shows Promise in Reducing Blood Lipids While Restoring Glucose Homeostasis

Sun, 22 Jun 2025 23:05:00 -0400

Hua Medicine Announces at 2025 ADA Scientific Sessions that Dorzagliatin Combined with DPP-4 Inhibitor Shows Promise in Reducing Blood Lipids While Restoring Glucose Homeostasis

Sun, 22 Jun 2025 23:05:00 -0400

Hua Medicine Announces at 2025 ADA Scientific Sessions that Dorzagliatin Combined with DPP-4 Inhibitor Shows Promise in Reducing Blood Lipids While Restoring Glucose Homeostasis

Sun, 22 Jun 2025 23:05:00 -0400

Hua Medicine Announces at 2025 ADA Scientific Sessions that Dorzagliatin Combined with DPP-4 Inhibitor Shows Promise in Reducing Blood Lipids While Restoring Glucose Homeostasis

Sun, 22 Jun 2025 23:05:00 -0400

Hua Medicine Announces 2024 Annual Results

Fri, 28 Mar 2025 08:51:00 -0400

SHANGHAI, Mar 28, 2025 - (JCN Newswire) - - Hua Medicine ("the Company", Hong Kong Stock Exchange Stock Code: 2552) announced the audited full-year results of the Company and its subsidiaries for the year ended December 31, 2024 (the "Reporting Period"), along with the Company's business progress in 2024 and future business outlook. Hua Medicine has made significant strides in the commercialization of its core product, the glucokinase activator (GKA) dorzagliatin (trade name: HuaTangNing, as well as in R&D innovation and manufacturing capacity optimization, laying a solid foundation for the Company's long-term sustainable development.

Highlights include:

- HuaTangNing completed its